Northwest Biotherapeutics, Inc. (BST:NBYB)
Germany · Delayed Price · Currency is EUR 0.2280
+0.0180 (8.57%)
At close: Nov 7, 2025
Northwest Biotherapeutics Company Description
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer.
The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient’s own immune system to attack cancer.
Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer.
The company also develops DCVax-Direct, that has completed Phase I clinical trials to treat inoperable solid tumors, as well as a range of types of cancers.
Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.
Northwest Biotherapeutics, Inc.
| Country | United States |
| Founded | 1996 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 25 |
| CEO | Linda Powers |
Contact Details
Address: 4800 Montgomery Lane Bethesda, Delaware 20814 United States | |
| Phone | 240 497 9024 |
| Website | nwbio.com |
Stock Details
| Ticker Symbol | NBYB |
| Exchange | Stuttgart Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Linda Powers | Chief Executive Officer |
| Linda Powers | Chief Financial Officer |
| David Innes | Head of Investor Relations |